Clinical Trial

Clinical Study of CD7 CAR-T Cells for Relapsed/refractory Autoimmune Diseases

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective was to evaluate the safety of CD7 CAR-T cells for the treatment of subjects with relapsed/refractory AID. CD7 CAR-T cells were infused in a single infusion in subjects who were screened after signing an informed consent form and undergoing single nucleus cell collection and pretreatment, and blood was collected before and after the infusion for pharmacokinetic, pharmacodynamic, immunogenicity, and safety evaluations.
Trial Details
NCT Number NCT06871644
Lead Sponsor PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Enrollment 18 participants
Start Date 2025-03-18
Primary Completion 2026-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-12